Laura Meléndez-Alafort

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7516548/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging. Molecules, 2022, 27, 264.	3.8	16
2	A feasibility study of the therapeutic application of a mixture of ^{67/64} Cu radioisotopes produced by cyclotrons with proton irradiation. Medical Physics, 2022, 49, 2709-2724.	3.0	10
3	225Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins. Molecules, 2022, 27, 2156.	3.8	5
4	Impact of Different [Tc(N)PNP]-Scaffolds on the Biological Properties of the Small cRGDfK Peptide: Synthesis, In Vitro and In Vivo Evaluations. Molecules, 2022, 27, 2548.	3.8	3
5	A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules, 2022, 27, 2617.	3.8	15
6	IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery. Pharmaceutics, 2022, 14, 1060.	4.5	2
7	Drug Delivery Systemsâ€Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy. Macromolecular Bioscience, 2021, 21, e2000362.	4.1	11
8	Preliminary dosimetric analysis of DOTA-folate radiopharmaceutical radiolabelled with ⁴⁷ Sc produced through ^{nat} V(p,x) ⁴⁷ Sc cyclotron irradiation. Physics in Medicine and Biology, 2021, 66, 025003.	3.0	12
9	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. Cellular and Molecular Immunology, 2021, 18, 1197-1210.	10.5	14
10	Bioconjugated technetium carbonyls by transmetalation reaction with zinc derivatives. Bioorganic and Medicinal Chemistry Letters, 2021, 37, 127840.	2.2	2
11	New Bioconjugated Technetium and Rhenium Folates Synthesized by Transmetallation Reaction with Zinc Derivatives. Molecules, 2021, 26, 2373.	3.8	2
12	Preclinical dosimetric studies of ¹⁷⁷ Luâ€scFvD2B and comparison with ¹⁷⁷ Luâ€PSMAâ€617 and ¹⁷⁷ Luâ€iPSMA endoradiotherapeutic agents. Medical Physic 2021, 48, 4064-4074.	s,3.0	3
13	Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. Scientific Reports, 2020, 10, 9313.	3.3	11
14	Synthesis and preclinical evaluation of the 99mTc-/177Lu-CXCR4-L theranostic pair for in vivo chemokine-4 receptor-specific targeting. Journal of Radioanalytical and Nuclear Chemistry, 2020, 324, 21-32.	1.5	16
15	Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy. Current Medicinal Chemistry, 2020, 27, 7032-7047.	2.4	5
16	177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Materials Science and Engineering C, 2019, 105, 110043.	7.3	42
17	Radiation effective dose assessment of [51Mn]- and [52Mn]-chloride. Applied Radiation and Isotopes, 2019, 153, 108805.	1.5	10
18	Internal radiation dose assessment of radiopharmaceuticals prepared with cyclotronâ€produced ^{99m} Tc. Medical Physics, 2019, 46, 1437-1446.	3.0	15

#	Article	IF	CITATIONS
19	Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles. Ecoproduction, 2019, , 201-219.	0.8	0
20	Experimental setup for light-to-heat NIR conversion measurements of gold nanoparticle solutions. Acta Scientifica Naturalis, 2019, 6, 91-99.	0.1	0
	[^{99m} Tc][Tc(N)(DASD)(PNP <i>n</i>)] ⁺ (DASD =) Tj ETQq1 1 0.784314 rgBT /Overlock	10 Tf 50 6	72 Td (1,4-
21	Imaging: Synthesis, Pharmacological and Pharmacokinetic Studies. Journal of Medicinal Chemistry, 2018. 61. 11114-11126.	6.4	10
22	Radioisotopic purity and imaging properties of cyclotron-produced ^{99m} Tc using direct ¹⁰⁰ Mo(<i>p</i> ,2 <i>n</i>) reaction. Physics in Medicine and Biology, 2018, 63, 185021.	3.0	17
23	[^{99m} Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of αvβ ₃ Integrin: Synthesis, Structure–Activity and Pharmacokinetic Studies. Journal of Medicinal Chemistry, 2018, 61, 9596-9610.	6.4	17
24	In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals. Applied Radiation and Isotopes, 2018, 139, 325-331.	1.5	35
25	Quality assurance of Mo-99/Tc-99m radionuclide generators. Acta Scientifica Naturalis, 2018, 5, 40-47.	0.1	2
26	In vitro cytotoxicity of allelopathic plants <i>Adonis vernalis</i> L. <i>Origanum vulgare</i> ssp. <i>vulgare</i> L. and <i>Nepeta nuda</i> subsp. <i>nuda</i> . Acta Scientifica Naturalis, 2018, 5, 64-69.	0.1	0
27	18th European Symposium on Radiopharmacy and Radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 2016, 1, .	3.9	2
28	A freeze-dried kit formulation for the preparation of Lys 27 (99m Tc-EDDA/HYNIC)-Exendin(9-39)/ 99m Tc-EDDA/HYNIC-Tyr 3 -Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology, 2015, 42, 911-916.	0.6	6
29	Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷ Lu and Conjugated to Peptides. Current Radiopharmaceuticals, 2015, 8, 150-159.	0.8	28
	Novel [^{99m} Tc ^{III} (PS) ₂ (Ln)] Mixed-Ligand Compounds (PS =) Tj ETQq0000	gBT /Over	lock 10 Tf 5
30	Agents: Synthesis, in Vitro, and ex Vivo Biodistribution Studies. Journal of Medicinal Chemistry, 2014, 57, 8960-8970.	6.4	6
31	[99mTc(N)PNP]-scaffold for SPECT of multidrug resistance: Early in-vitro study. Nuclear Medicine and Biology, 2014, 41, 618.	0.6	0
32	Inhibition of growth and induction of apoptosis in human lung cancer cells by Br-oxph. Genetika, 2014, 46, 1-10.	0.4	4
33	Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 476-499.	1.7	14
34	Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms. Current Pharmaceutical Design, 2012, 18, 1098-1106.	1.9	25
35	New Bioconjugated Rhenium Carbonyls by Transmetalation Reaction with Zinc Derivatives. Organometallics, 2012, 31, 5884-5893.	2.3	11
36	Peptides for In Vivo Target-Specific Cancer Imaging. Mini-Reviews in Medicinal Chemistry, 2010, 10, 87-97.	2.4	37

#	Article	IF	CITATIONS
37	Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. Nuclear Medicine and Biology, 2009, 36, 693-701.	0.6	18
38	Detection of sites of infection in mice using 99mTc-labeled PN2S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study. Nuclear Medicine and Biology, 2009, 36, 57-64.	0.6	36
39	Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nuclear Medicine and Biology, 2009, 36, 525-533.	0.6	22
40	A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent <i>In vivo</i> Therapeutic Activity. Clinical Cancer Research, 2008, 14, 3598-3606.	7.0	86
41	Simulations and tests for metabolic radiotherapy with 188Re. Nuclear Physics, Section B, Proceedings Supplements, 2007, 172, 303-307.	0.4	Ο
42	188Rhenium-induced cell death and apoptosis in a panel of tumor cell lines. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 471-474.	1.6	6
43	A YAP camera for the biodistribution of 188Re conjugated with Hyaluronic-Acid in "in vivo―systems. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 484-487.	1.6	4
44	Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy. Current Pharmaceutical Analysis, 2006, 2, 339-352.	0.6	28
45	Bioavailability of99mTc-Ha-paclitaxel complex [99mTc-ONCOFID-P] in mice using four different administration routes. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 939-950.	1.0	16
46	Kit for instant 99mTc labeling of the antimicrobial peptide ubiquicidin 29-41. Journal of Radioanalytical and Nuclear Chemistry, 2005, 266, 307-311.	1.5	13
47	Molecular recognition and stability of 99mTc-UBI 29–41 based on experimental and semiempirical results. Applied Radiation and Isotopes, 2004, 61, 1261-1268.	1.5	17
48	Biokinetics of 99mTc-UBI 29-41 in humans. Nuclear Medicine and Biology, 2004, 31, 373-379.	0.6	71
49	Preparation via coligand exchange and characterization of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]Octreotide (99mTc-EDDA/HYNIC-TOC). Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 307-318.	1.0	31
50	Labeling of biotin with [166Dy]Dy/166Ho as a stable in vivo generator system. International Journal of Pharmaceutics, 2003, 255, 129-138.	5.2	14
51	In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nuclear Medicine and Biology, 2003, 30, 597-603.	0.6	66
52	Lys and Arg in UBI: A specific site for a stable Tc-99m complex?. Nuclear Medicine and Biology, 2003, 30, 605-615.	0.6	32
53	Optimization of the small-scale synthesis of DOTA-Tyr3-octreotide. Nuclear Medicine Communications, 2002, 23, 493-499.	1.1	5
54	99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats. International Journal of Pharmaceutics, 2002, 233, 29-34.	5.2	20

Laura Meléndez-Alafort

#	Article	IF	CITATIONS
55	Labelling of Re-ABP with 188Re for bone pain palliation. Applied Radiation and Isotopes, 2001, 54, 435-442.	1.5	15
56	Labelling of octreotide using76Br-prosthetic groups. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 561-573.	1.0	9
57	¹⁸⁸ Rhenium″abelling of hynicâ€{Tyr ³]octreotide. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S685.	1.0	Ο
58	99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. Journal of Nuclear Medicine, 2000, 41, 1114-9.	5.0	98
59	A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. BMJ: British Medical Journal, 1999, 319, 1054-1059.	2.3	609
60	Labeling peptides with rhenium-188. International Journal of Pharmaceutics, 1999, 182, 165-172.	5.2	14
61	Preparation and Pharmacokinetics of Samarium(III)-153-Labeled DTPA-bis-Biotin. Characterization and Theoretical Studies of the Samarium(III)-152 Conjugate. Bioconjugate Chemistry, 1999, 10, 726-734.	3.6	19
62	Radiopharmacokinetics, Renal Clearance and Dosimetry of 99mTc-MAG3. Archives of Medical Research, 1999, 30, 49-54.	3.3	0
63	Preparation, biodistribution, and dosimetry of 188Re-Labeled MoAb ior cea1 and its f(ab′)2 fragments by avidin-biotin strategy. Nuclear Medicine and Biology, 1999, 26, 57-62.	0.6	22
64	Radiopharmacokinetic data for 99mTc-ABP—A new radiopharmaceutical for bone scanning: Comparison with 99mTc-MDP. Nuclear Medicine and Biology, 1997, 24, 27-33.	0.6	16
65	Technetium-99m-alendronate: a new radiopharmaceutical for bone scanning. Archives of Medical Research, 1996, 27, 481-3.	3.3	3
66	Synthesis and Cytostatic Activity of 4-bromo-5-ethyl-2-(ethylamino)- 5-methyl-5H-1,2-oxaphosphole 2-oxide. Journal of Applied Pharmaceutical Science, 0, , .	1.0	0